Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant-Reference-Cited by-同舟云学术

Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant

Published:2019-01-03 Issue:1 Volume:8 Page:
ISSN:2162-3619
Container-title:Experimental Hematology & Oncology
language:en
Short-container-title:Exp Hematol Oncol

Author:

Fan Yun,Artz Andrew S.,van Besien Koen,Stock Wendy,Larson Richard A.,Odenike Olatoyosi,Godley Lucy A.,Kline Justin,Cunningham John M.,LaBelle James L.,Bishop Michael R.,Liu Hongtao^ORCID

Funder

Cancer Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s40164-018-0125-6.pdf

Reference18 articles.

1. Petrovic A, Hale G. Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Expert Rev Clin Immunol. 2011;7(4):515–25.

2. Radich JP, Sanders JE, Buckner CD, Martin PJ, Petersen FB, Bensinger W. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11:304–13.

3. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant. 2005;36:157–62.